about
Molecular mechanism of copper transport in Wilson disease.Molecular mechanisms of in vivo metal chelation: implications for clinical treatment of metal intoxicationsCopper Homeostasis as a Therapeutic Target in Amyotrophic Lateral Sclerosis with SOD1 MutationsCombination Therapy Using Chelating Agent and Zinc for Wilson’s DiseaseRed cell aplasia following prolonged D-penicillamine therapyOcular myasthenia gravis after D-penicillamine administration.Nephrotic syndrome induced by penicillamineHigh performance liquid chromatography analysis of D-penicillamine by derivatization with N-(1-pyrenyl)maleimide (NPM).Poor cognitive development and abdominal pain: Wilson's disease.Chronic inorganic mercury poisoning treated with N-acetyl-D-penicillamine.The skin in genetically-controlled metabolic disordersEffect of D-penicillamine treatment on brain metabolism in Wilson's disease: a case study.Exchange of ceruloplasmin copper with ionic Cu64 with reference to Wilson's disease.Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease.Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.Disease modifying drugs for rheumatoid arthritis: yesterday's treatment today or today's treatment tomorrow?Zinc acetate for the treatment of Wilson's disease.Effective treatment of Wilson's disease with oral zinc sulphate: two case reports.Liver mitochondrial membrane crosslinking and destruction in a rat model of Wilson disease.A comparative study of in vitro and in vivo interaction of D-penicillamine and triethylenetetramine with copper.Tetrathiomolybdate anticopper therapy for Wilson's disease inhibits angiogenesis, fibrosis and inflammation.Antiangiogenic therapy through copper chelation.1H NMR-based metabolomics investigation of copper-laden rat: a model of Wilson's disease.Current and future therapy in haemochromatosis and Wilson's disease.Haplotype studies in Wilson diseaseWilson's disease: clinical, genetic and pharmacological findings.Novel therapeutic approaches to the treatment of Wilson's disease.Presentation, diagnosis and outcome of predominantly hepatic Wilson's disease in adult Saudi patients: a single centre experience.Wilson's disease in one identical twin and treatment by triethylene tetramine 2HCl in another case.Hereditary iron and copper deposition: diagnostics, pathogenesis and therapeutics.Microbial peptide de-coppers mitochondria: implications for Wilson disease.Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's diseaseNew developments in therapeutic chelating agents as antidotes for metal poisoning.Metal attenuating therapies in neurodegenerative disease.Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.Treatment of Wilson's disease motor complications with deep brain stimulation.Capillary electrophoresis in the analysis of biologically important thiols.Wilson's disease: the 60th anniversary of Walshe's article on treatment with penicillamine.Disposition of d-penicillamine, a promising drug for preventing alcohol-relapse. Influence of dose, chronic alcohol consumption and age: studies in rats.Cystinuria.
P2860
Q24812338-3CE40B24-891B-46D6-B67C-E04A26B555ACQ24812715-C1969E7D-F6BF-4EE2-96A6-A8F2821F694BQ26748245-1127B04F-C981-4845-A308-802B7D26D796Q26773881-2517CF4A-AEF0-469F-8255-8C43202DE5B0Q28330037-0635215F-871B-4C42-893F-3FCCE0F9FBF0Q28355626-59C064FC-EF51-4D15-AA3B-80B607D8A7FCQ28365402-3A311785-7D17-4F18-8EAF-2C4FA5F43645Q30633103-E8D8399A-38B0-42EF-8986-61C482EBDA77Q31032905-753CEF02-DDD5-4A71-B5AB-3F718DB50619Q33576590-02FB0F1C-39B7-4BEB-9F73-F4FF23483455Q33585598-345DCCE3-0BEA-496E-8779-06EDD69544C4Q33631469-4CA07772-6698-4A03-813C-60FC0491AE3EQ33731862-A793947B-EF12-4426-A5FD-DE9794DCF4A1Q34190413-20B45E56-EEB5-40C0-AED0-CF195593B26BQ34282333-93A795BC-2252-459A-B44B-DC6D8710B53DQ34357618-C3D40B39-58BE-4975-8258-DFB35187F01FQ34390366-53B06226-44FC-4FCD-B0FC-E51A46746D95Q34550762-E61E63AE-630C-4A9D-BCE6-1F314398193FQ34749046-47AE1251-D5CA-4558-93C1-83A32DA24616Q34878890-3BD077E3-C08E-4D4B-90C1-C5AC5F2CEC39Q35136117-A76383FD-47A3-4436-9D85-C8438BBAFF2CQ35143913-B3788279-EBEE-4726-9F0F-595F7055DCB9Q35300486-B2E86186-67F4-49AE-9BA6-0BDC57F2AC4BQ35593984-17467FAE-AADF-4D2D-94C8-8CDCF2BB1B52Q35888860-D23B44CE-9D14-4787-977D-C7CB512D8EADQ36033407-B317BD09-1EE9-4C8E-B68E-4BF13AE523D9Q36382586-9312D3CA-978D-43CF-9E23-58BF0274315EQ36404886-3ED77871-EF86-47E4-AA44-837CEAE6FF11Q36749843-D2BB7670-5B88-4491-9C8C-6A431C5868AAQ36823912-D6ABD0A1-90A3-48FD-803E-B257A9413B97Q37042204-76DB3676-49CA-4D7D-8CCE-031F73004218Q37428097-80D25D58-F9AE-4DFE-8CBB-F11A9A1075DBQ37731908-63D3B6A3-FE62-437D-A658-103664DB2F59Q37957126-2BA4B01E-200F-45FD-85D9-A1D8A76B48ABQ38100669-EFC0BD90-C275-4899-9DEE-79207F89C95DQ38189115-5EA99B64-B8B7-4600-97EB-CECB7F196E89Q38822925-060D038A-8A76-4911-B068-258EDFCD1F72Q39093783-3973B92C-25F1-45D0-B74E-7971F562FB13Q39233372-A399ECCC-F9BB-41F9-8386-4E2E2F2A5BBCQ39581538-6469D46B-8630-47C2-B2D9-4433B78AB7AB
P2860
description
1956 nî lūn-bûn
@nan
1956 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1956 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1956年の論文
@ja
1956年論文
@yue
1956年論文
@zh-hant
1956年論文
@zh-hk
1956年論文
@zh-mo
1956年論文
@zh-tw
1956年论文
@wuu
name
Penicillamine, a new oral therapy for Wilson's disease.
@ast
Penicillamine, a new oral therapy for Wilson's disease.
@en
Penicillamine, a new oral therapy for Wilson's disease.
@nl
type
label
Penicillamine, a new oral therapy for Wilson's disease.
@ast
Penicillamine, a new oral therapy for Wilson's disease.
@en
Penicillamine, a new oral therapy for Wilson's disease.
@nl
prefLabel
Penicillamine, a new oral therapy for Wilson's disease.
@ast
Penicillamine, a new oral therapy for Wilson's disease.
@en
Penicillamine, a new oral therapy for Wilson's disease.
@nl
P1476
Penicillamine, a new oral therapy for Wilson's disease.
@en
P2093
P304
P356
10.1016/0002-9343(56)90066-3
P407
P577
1956-10-01T00:00:00Z